{"entity":{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","aka":[],"tldr":"The Royal Marsden was the world's first hospital dedicated to cancer (1851) and is paired with the Institute of Cancer Research.","summary":"The Royal Marsden in London was the world's first hospital dedicated to cancer, opened in 1851, and works as a pair with The Institute of Cancer Research; it ranks seventh in the Newsweek/Statista oncology list. Together they discovered abiraterone and worked out the clinical path for olaparib and PARP inhibition in BRCA-mutated cancers, with Johann de Bono and Andrew Tutt central, and the hospital leads the STAMPEDE prostate platform and breast trials while pioneering MR-linac adaptive radiotherapy. OnCo links it to the KEYNOTE-048 head and neck paper, to prostate, mesothelioma, sarcoma and neuroendocrine tumour pages, and to bottlenecks about surgery and radiotherapy being under-funded relative to drugs. The question it keeps raising is how to fund trials of treatments no company owns. Stephen Johnston and James Larkin are among the people listed here.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/The_Royal_Marsden_NHS_Foundation_Trust","links":[{"label":"Official website","url":"https://www.royalmarsden.nhs.uk"}],"tags":[],"related":["icr-london"],"cancers":["colorectal","nsclc","lung-cancer","prostate","prostate-mcrpc"],"sections":[],"technologies":["mr-linac","parp-inhibitor"],"targets":[],"drugs":["olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mercury","pace-b"],"people":["stephen-johnston","andrew-tutt","david-cunningham","james-larkin","johann-de-bono","nicholas-james","nicholas-turner","uwe-oelfke","karl-munslow-ong","naureen-starling","ian-chau","sanjay-popat","nicholas-van-as","ros-eeles"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.49,"lng":-0.172,"institutionType":"cancer-center","website":"https://www.royalmarsden.nhs.uk","newsweekOncology2026":7,"programs":["Prostate cancer (abiraterone, PARP)","MR-linac","Breast cancer"]},"route":"/institutions/royal-marsden/","neighbours":{"institution":[{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/"},{"id":"cruk-convergence-science-centre","kind":"institution","name":"Cancer Research UK Convergence Science Centre","route":"/institutions/cruk-convergence-science-centre/"},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/"},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"}],"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"trial":[{"id":"abc-07","kind":"trial","name":"ABC-07","route":"/trials/abc-07/"},{"id":"c-trak-tn","kind":"trial","name":"c-TRAK TN","route":"/trials/c-trak-tn/"},{"id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/"},{"id":"mercury","kind":"trial","name":"MERCURY","route":"/trials/mercury/"},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/"},{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/"},{"id":"precision-panc","kind":"trial","name":"Precision-Panc","route":"/trials/precision-panc/"},{"id":"safir-abc10","kind":"trial","name":"SAFIR-ABC10","route":"/trials/safir-abc10/"},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/"},{"id":"tnt","kind":"trial","name":"TNT (Triple Negative Trial)","route":"/trials/tnt/"},{"id":"tracc","kind":"trial","name":"TRACC","route":"/trials/tracc/"}],"person":[{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/"},{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/"},{"id":"david-cunningham","kind":"person","name":"David Cunningham","route":"/people/david-cunningham/"},{"id":"dearbhaile-collins","kind":"person","name":"Dearbhaile Collins","route":"/people/dearbhaile-collins/"},{"id":"ian-chau","kind":"person","name":"Ian Chau","route":"/people/ian-chau/"},{"id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/"},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/"},{"id":"karl-munslow-ong","kind":"person","name":"Karl Munslow-Ong","route":"/people/karl-munslow-ong/"},{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","route":"/people/kevin-harrington/"},{"id":"mitch-dowsett","kind":"person","name":"Mitch Dowsett","route":"/people/mitch-dowsett/"},{"id":"naureen-starling","kind":"person","name":"Naureen Starling","route":"/people/naureen-starling/"},{"id":"nicholas-james","kind":"person","name":"Nicholas James","route":"/people/nicholas-james/"},{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/"},{"id":"nicholas-van-as","kind":"person","name":"Nicholas van As","route":"/people/nicholas-van-as/"},{"id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/"},{"id":"ros-eeles","kind":"person","name":"Rosalind Eeles","route":"/people/ros-eeles/"},{"id":"sanjay-popat","kind":"person","name":"Sanjay Popat","route":"/people/sanjay-popat/"},{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","route":"/people/stephen-johnston/"},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/"},{"id":"uwe-oelfke","kind":"person","name":"Uwe Oelfke","route":"/people/uwe-oelfke/"}],"paper":[{"id":"paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019","kind":"paper","name":"Assessment of molecular relapse detection in early-stage breast cancer","route":"/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/"},{"id":"paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016","kind":"paper","name":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","route":"/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/"},{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/"},{"id":"paper-garcia-murillas-ctdna-mutation-tracking-stm-2015","kind":"paper","name":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","route":"/key-papers/paper-garcia-murillas-ctdna-mutation-tracking-stm-2015/"},{"id":"paper-attard-abiraterone-phase-1-cyp17-jco-2008","kind":"paper","name":"Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven","route":"/key-papers/paper-attard-abiraterone-phase-1-cyp17-jco-2008/"},{"id":"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","kind":"paper","name":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","route":"/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/"},{"id":"paper-stampede-abiraterone-nejm-2017","kind":"paper","name":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","route":"/key-papers/paper-stampede-abiraterone-nejm-2017/"},{"id":"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","kind":"paper","name":"SU2C-PCF: integrative clinical genomics of advanced prostate cancer","route":"/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/"},{"id":"paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026","kind":"paper","name":"The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS","route":"/key-papers/paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026/"},{"id":"paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015","kind":"paper","name":"TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer","route":"/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"bottleneck":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/"}],"idea":[{"id":"idea-fund-global-academic-phase-one-network","kind":"idea","name":"A global first-in-human network for academic cancer trials with single ethics review","route":"/ideas/idea-fund-global-academic-phase-one-network/"},{"id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","route":"/ideas/idea-tr1-tumour-board-trial-line-item/"},{"id":"idea-tr2-combination-utility","kind":"idea","name":"A non-profit phase 1b combination unit that any drug owner can use","route":"/ideas/idea-tr2-combination-utility/"},{"id":"idea-fund-surgical-trials-network","kind":"idea","name":"A permanently funded international network for randomised cancer surgery trials","route":"/ideas/idea-fund-surgical-trials-network/"},{"id":"idea-fund-non-drug-trial-quota","kind":"idea","name":"A statutory minimum share of public trial money for surgery and radiotherapy","route":"/ideas/idea-fund-non-drug-trial-quota/"},{"id":"idea-tr1-evening-weekend-trial-clinics","kind":"idea","name":"Evening and weekend trial clinics for working-age patients","route":"/ideas/idea-tr1-evening-weekend-trial-clinics/"}]}}